FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

0

	APPROVAL
	er: 3235-0287
l	erage burden
	sponse: 0.5
	rerage burden

WNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>HOLLER FRANK A</u>				2. Issuer Name and Ticker or Trading Symbol Xenon Pharmaceuticals Inc. [XENE]										ck all ap _l	olicable)	g Person(s) to I	ssuer Owner	
(Last) 200 - 365	(Fir	,	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 09/19/2019									Offic belo	er (give title w)	Other below	(specify)	
(Street) BURNAI (City)			Zip)		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc Line)	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
		Tabl	e I - Nor	n-Deriv	ative	Se	curitie	s Ac	quired	, Dis	posed o	f, or I	Bene	ficially	/ Own	ed		
			2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Code (Instr.						Secur Benef	icially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A (D) or	Price	Trans	action(s) 3 and 4)		(111501.4)
Common	Shares			09/19	9/2019)			S		7,600		D S	\$9.27 ⁽¹⁾	27 ⁽¹⁾ 124,161 D			
Common	Shares			09/20)/2019)			S		5,206		D S	\$9.39(2)	9.39 ⁽²⁾ 118,955 D			
		Та									sed of, onvertib				wned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Day	Date,		Transaction Code (Instr.		n of		Exercis on Dat Day/Ye		7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		De Se (In	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amou or Numl of Share	ber				

Explanation of Responses:

- 1. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from \$9.25 to \$9.30, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein
- 2. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from \$9.33 to \$9.45, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein

Remarks:

/s/ Sherry Aulin, Attorney-in-

09/20/2019

<u>fact</u>

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.